{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T19:46:54Z","timestamp":1740167214098,"version":"3.37.3"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2023,4,12]],"date-time":"2023-04-12T00:00:00Z","timestamp":1681257600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,4,12]],"date-time":"2023-04-12T00:00:00Z","timestamp":1681257600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ophthalmol Ther"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1007\/s40123-023-00707-y","type":"journal-article","created":{"date-parts":[[2023,4,12]],"date-time":"2023-04-12T06:02:36Z","timestamp":1681279356000},"page":"1787-1793","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Clinical Outcomes of Topical 0.1% Ciclosporin Cationic Emulsion Used on Label in Children with Vernal Keratoconjunctivitis"],"prefix":"10.1007","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2617-0289","authenticated-orcid":false,"given":"Giuseppe","family":"Giannaccare","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Costanza","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Massimiliano","family":"Borselli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiara","family":"Bonzano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanna","family":"Carnovale Scalzo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Massimo","family":"Nicol\u00f2","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincenzo","family":"Scorcia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlo Enrico","family":"Traverso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aldo","family":"Vagge","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,4,12]]},"reference":[{"key":"707_CR1","doi-asserted-by":"crossref","unstructured":"Lallemand F, Daull P, Benita S, Buggage R, Garrigue J-S. Successfully improving ocular drug delivery using the cationic nanoemulsion, novasorb. 2012;2012:604204","DOI":"10.1155\/2012\/604204"},{"issue":"2\u20133","key":"707_CR2","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/0378-5173(89)90047-1","volume":"55","author":"Y Rojanasakul","year":"1989","unstructured":"Rojanasakul Y, Robinson JR. Transport mechanisms of the cornea: characterization of barrier permselectivity. Int J Pharm. 1989;55(2\u20133):237\u201346.","journal-title":"Int J Pharm"},{"key":"707_CR3","doi-asserted-by":"publisher","first-page":"604204","DOI":"10.1155\/2012\/604204","volume":"2012","author":"F Lallemand","year":"2012","unstructured":"Lallemand F, Daull P, Benita S, Buggage R, Garrigue JS. Successfully improving ocular drug delivery using the cationic nanoemulsion, novasorb. J Drug Deliv. 2012;2012:604204. https:\/\/doi.org\/10.1155\/2012\/604204.","journal-title":"J Drug Deliv"},{"key":"707_CR4","first-page":"15e34","volume":"21","author":"TF Vandamme","year":"2002","unstructured":"Vandamme TF. Microemulsions as ocular drug delivery systems: recent developments and future challenges. Prog RetinEye Res. 2002;21:15e34.","journal-title":"Prog RetinEye Res."},{"key":"707_CR5","unstructured":"European Medicines Agency. Verkazia. Annex 1: Summary of product characteristics (SmPC). https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/verkazia-epar-product-information_en.pdf. Accessed 13 Nov 2019."},{"issue":"4","key":"707_CR6","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1038\/sj.eye.6700675","volume":"18","author":"S Bonini","year":"2004","unstructured":"Bonini S, Coassin M, Aronni S, Lambiase A. Vernal keratoconjunctivitis. Eye. 2004;18(4):345\u201351. https:\/\/doi.org\/10.1038\/sj.eye.6700675.","journal-title":"Eye"},{"issue":"5","key":"707_CR7","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/j.ophtha.2018.12.027","volume":"126","author":"A Leonardi","year":"2019","unstructured":"Leonardi A, Doan S, Amrane M, et al. A randomized, controlled trial of ciclosporin A cationic emulsion in pediatric vernal keratoconjunctivitis: the VEKTIS study. Ophthalmology. 2019;126(5):671\u201381. https:\/\/doi.org\/10.1016\/j.ophtha.2018.12.027.","journal-title":"Ophthalmology"},{"issue":"5","key":"707_CR8","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1007\/s40272-016-0185-1","volume":"18","author":"S Esposito","year":"2016","unstructured":"Esposito S, Fior G, Mori A, Osnaghi S, Ghiglioni D. An update on the therapeutic approach to vernal keratoconjunctivitis. Pediatr Drugs. 2016;18(5):347\u201355. https:\/\/doi.org\/10.1007\/s40272-016-0185-1.","journal-title":"Pediatr Drugs"},{"issue":"4","key":"707_CR9","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1111\/pai.12197","volume":"25","author":"P Vichyanond","year":"2014","unstructured":"Vichyanond P, Pacharn P, Pleyer U, Leonardi A. Vernal keratoconjunctivitis: a severe allergic eye disease with remodeling changes. Pediatr Allergy Immunol. 2014;25(4):314\u201322. https:\/\/doi.org\/10.1111\/pai.12197.","journal-title":"Pediatr Allergy Immunol"},{"issue":"1","key":"707_CR10","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1136\/bjophthalmol-2011-301376","volume":"97","author":"S De Smedt","year":"2013","unstructured":"De Smedt S, Wildner G, Kestelyn P. Vernal keratoconjunctivitis: an update. Br J Ophthalmol. 2013;97(1):9\u201314. https:\/\/doi.org\/10.1136\/bjophthalmol-2011-301376.","journal-title":"Br J Ophthalmol"},{"issue":"Suppl 2","key":"707_CR11","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1136\/vr.102484","volume":"174","author":"P Forsythe","year":"2014","unstructured":"Forsythe P, Paterson S. Ciclosporin 10 years on: indications and efficacy. Vet Rec. 2014;174(Suppl 2):13\u201321. https:\/\/doi.org\/10.1136\/vr.102484.","journal-title":"Vet Rec"},{"issue":"4","key":"707_CR12","doi-asserted-by":"publisher","first-page":"287","DOI":"10.5301\/ejo.5000779","volume":"26","author":"A Leonardi","year":"2016","unstructured":"Leonardi A, Van Setten G, Amrane M, et al. Efficacy and safety of 0.1% cyclosporine A cationic emulsion in the treatment of severe dry eye disease: a multicenter randomized trial. Eur J Ophthalmol. 2016;26(4):287\u201396. https:\/\/doi.org\/10.5301\/ejo.5000779.","journal-title":"Eur J Ophthalmol"},{"key":"707_CR13","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.ajo.2019.11.020","volume":"212","author":"D Bremond-Gignac","year":"2020","unstructured":"Bremond-Gignac D, Doan S, Amrane M, et al. Twelve-month results of ciclosporin A cationic emulsion in a randomized study in patients with pediatric vernal keratoconjunctivitis. Am J Ophthalmol. 2020;212:116\u201326. https:\/\/doi.org\/10.1016\/j.ajo.2019.11.020.","journal-title":"Am J Ophthalmol"},{"issue":"5","key":"707_CR14","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1097\/ACI.0b013e3282efb726","volume":"7","author":"S Bonini","year":"2007","unstructured":"Bonini S, Sacchetti M, Mantelli F, Lambiase A. Clinical presentation of vernal keratoconjunctivitis. Curr Opin Allergy Clin Immunol. 2007;7(5):436\u201341.","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"707_CR15","doi-asserted-by":"publisher","first-page":"3589","DOI":"10.2147\/OPTH.S370414","volume":"16","author":"T Bouricer","year":"2022","unstructured":"Bouricer T, Dory A, Dormegny L, Alcazar J, Gaucher D, Sauer A. Efficacy and safety of 0.1% ciclosporin versus 2% ciclosporin in the treatment of severe vernal keratoconjunctivitis in children. Clin Ophthalmol. 2022;16:3589\u201396.","journal-title":"Clin Ophthalmol"},{"key":"707_CR16","doi-asserted-by":"publisher","DOI":"10.1080\/09273948.2022.2103833","author":"E Salami","year":"2022","unstructured":"Salami E, Righetti G, Cavarzeran F, Leonardi A. Efficacy and satisfaction of ciclosporin 0.1% in patients with vernal keratoconjunctivitis. Ocul Immunol Inflamm. 2022. https:\/\/doi.org\/10.1080\/09273948.2022.2103833.","journal-title":"Ocul Immunol Inflamm"},{"issue":"4","key":"707_CR17","doi-asserted-by":"publisher","first-page":"279","DOI":"10.3928\/01913913-20220420-03","volume":"59","author":"DG Ghiglioni","year":"2022","unstructured":"Ghiglioni DG, Bruschi G, Centonze S, et al. Cyclosporine A 0.1% cationic emulsion in vernal keratoconjunctivitis. J Pediatr Ophthalmol Strabismus. 2022;59(4):279. https:\/\/doi.org\/10.3928\/01913913-20220420-03.","journal-title":"J Pediatr Ophthalmol Strabismus"},{"issue":"1","key":"707_CR18","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/s1350-9462(01)00017-9","volume":"21","author":"TF Vandamme","year":"2002","unstructured":"Vandamme TF. Microemulsions as ocular drug delivery systems: recent developments and future challenges. Prog Retin Eye Res. 2002;21(1):15\u201334. https:\/\/doi.org\/10.1016\/s1350-9462(01)00017-9.","journal-title":"Prog Retin Eye Res"},{"key":"707_CR19","doi-asserted-by":"publisher","first-page":"678","DOI":"10.5301\/ejo.5001002","volume":"27","author":"C Baudouin","year":"2017","unstructured":"Baudouin C, de la Maza MS, Amrane M, et al. One-year efficacy and safety of 0.1% ciclosporin A cationic emulsion in the treatment of severe dry eye disease. Eur J Ophthalmol. 2017;27:678\u201385. https:\/\/doi.org\/10.5301\/ejo.5001002.","journal-title":"Eur J Ophthalmol"}],"container-title":["Ophthalmology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40123-023-00707-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40123-023-00707-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40123-023-00707-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,6]],"date-time":"2023-05-06T09:25:42Z","timestamp":1683365142000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40123-023-00707-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,12]]},"references-count":19,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["707"],"URL":"https:\/\/doi.org\/10.1007\/s40123-023-00707-y","relation":{},"ISSN":["2193-8245","2193-6528"],"issn-type":[{"type":"print","value":"2193-8245"},{"type":"electronic","value":"2193-6528"}],"subject":[],"published":{"date-parts":[[2023,4,12]]},"assertion":[{"value":"3 February 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 March 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 April 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}